公开(公告)号：US10646638B2

公开(公告)日：2020-05-12

申请号：US15647850

申请日：2017-07-12

申请人： Gary L. McNeil

发明人： Gary L. McNeil

IPC分类号： A61M1/36 ,  B01J20/32 ,  A61M1/34 ,  G01N33/564 ,  A61B5/15 ,  A61B6/03

摘要： The present invention relates to a method and apparatus for the isolation, modification and re-administration of a molecule or biomolecule, or a class of biomolecules, from the body fluid of a mammal via an extracorporeal closed circuit device. The device is able to capture and modify the biomolecule by the covalent or non-covalent attachment of a secondary molecule or protein, by cross-linking the captured molecule, or by altering the structure of the molecule (for example, by deglycosylation, peptide cleavage, or aggregation). The apparatus can be used to return the modified molecule or biomolecule to the mammalian subject. The device and methods may be utilized for the patient-specific diagnosis and/or treatment of a disease state which presents an associated molecule or protein in plasma or any other fluidized physiological system. The methods and apparatus may also be employed as a closed system allowing the on-line purification and/or modification of a target molecule or biomolecule from a fluid source such as a bioreactor or perfusion bioreactor.

公开(公告)号：US10646512B2

公开(公告)日：2020-05-12

申请号：US15407080

申请日：2017-01-16

申请人： NORGINE BV

发明人： Marc Halphen ,  Hans-Jurgen Gruss ,  Ian Cox ,  Alasdair Cockett ,  Peter Stein ,  Alex Ungar

IPC分类号： A61K31/375 ,  A61K31/765 ,  A61K47/06 ,  A61K47/22 ,  A61K9/08 ,  A61K33/04 ,  A61K33/14 ,  A61K9/00 ,  A61K47/02 ,  A61K31/77

摘要： The invention provides a colon cleansing solution comprising: a) 300 to 2000 mmol per litre ascorbate anion provided by ascorbic acid, one or more salts of ascorbic acid, or a mixture thereof; and b) 10 to 200 g per litre polyethylene glycol. The invention also provides methods and kits associated with, or making use of the solutions. The invention also provides a method of cleansing the colon of a subject comprising: —administering to the subject an effect amount of a first cleansing solution; and then after a time interval—administering to the subject an effective amount of a second cleansing solution, wherein the two cleansing solutions are as described in the specification.

公开(公告)号：US10266608B2

公开(公告)日：2019-04-23

申请号：US15146540

申请日：2016-05-04

申请人： EPIMAB BIOTHERAPEUTICS INC.

发明人： Chengbin Wu

IPC分类号： C07K16/46 ,  A61K39/00 ,  A61K39/395 ,  C07K16/00 ,  C07K16/28 ,  C07K16/24 ,  A61K45/06

摘要： The present invention provides multivalent and multispecific binding proteins that are capable of binding two or more antigens, or two or more epitopes. The present invention also provides methods of making and using such multivalent and multispecific binding proteins, including methods of using such binding proteins for prevention or treatment of various diseases, or for detecting specific antigens in vitro or in vivo.

公开(公告)号：US09295713B2

公开(公告)日：2016-03-29

申请号：US13233916

申请日：2011-09-15

申请人： Richard J. H. Smith ,  Yuzhou Zhang ,  Henry C. Marsh

发明人： Richard J. H. Smith ,  Yuzhou Zhang ,  Henry C. Marsh

IPC分类号： A61K38/00 ,  A61P13/12 ,  A61K38/17

CPC分类号： A61K38/177 ,  A61K38/1725

摘要： A method is disclosed for treating nephropathies involving undesired alternative pathway complement activation by administration of a complement inhibitory protein such as soluble complement receptor type I (sCR1).

摘要翻译： 公开了一种通过施用补体抑制蛋白例如可溶性补体受体I型（sCR1）来治疗涉及不期望的替代途径补体活化的肾病的方法。

公开(公告)号：US09266950B2

公开(公告)日：2016-02-23

申请号：US13937946

申请日：2013-07-09

申请人： ABBVIE INC.

发明人： Robert K. Hickman

IPC分类号： C07K16/24 ,  C07K16/06 ,  C07K1/14 ,  C07K1/16 ,  C07K1/18 ,  C07K1/20 ,  C07K1/22 ,  A61K39/395

CPC分类号： C07K16/244 ,  A61K39/39525 ,  C07K1/14 ,  C07K1/16 ,  C07K1/165 ,  C07K1/18 ,  C07K1/20 ,  C07K1/22 ,  C07K1/36 ,  C07K16/065 ,  C07K2317/24 ,  C07K2317/76

摘要： Disclosed herein are methods for the isolation and purification of anti-IL-13 antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise pH viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography (e.g., Protein A affinity chromatography), ion exchange chromatography, and hydrophobic chromatography. Further, the present invention is directed toward pharmaceutical compositions comprising one or more antibodies of the present invention.

摘要翻译： 本文公开了分离和纯化抗IL-13抗体的方法，其中使用亲和层析步骤导致抗体组合物对于药物用途而言足够纯。 本文描述的方法包括pH病毒还原/失活，超滤/渗滤，亲和层析（例如蛋白A亲和层析），离子交换层析和疏水层析。 此外，本发明涉及包含本发明的一种或多种抗体的药物组合物。

公开(公告)号：US08716449B2

公开(公告)日：2014-05-06

申请号：US11185615

申请日：2005-07-19

申请人： Maurice Kent Gately ,  David Howard Presky

发明人： Maurice Kent Gately ,  David Howard Presky

IPC分类号： C07K16/00 ,  C12P21/08 ,  C07K1/00

CPC分类号： C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6869

摘要： The present invention relates to novel p75 heterodimer specific anti-human IL-12 antibodies that are characterized by a higher potency and greater efficacy in neutralizing human IL-12 bioactivity than known heterodimer specific IL-12 monoclonal antibodies. The heterodimer specific antibodies recognize one or more epitopes of the human IL-12 p75 heterodimer, but do not bind to the p40 subunit alone. The heterodimer specific IL-12 antibodies neutralize rhesus monkey IL-12 bioactivity with a potency similar to their potency for neutralizing human IL-12 bioactivity making them useful IL-12 antagonists for in vivo studies in the rhesus monkey.

摘要翻译： 本发明涉及新型p75异二聚体特异性抗人IL-12抗体，其特征在于比已知的异二聚体特异性IL-12单克隆抗体具有更高的效力和更高的中和人IL-12生物活性的功效。 异源二聚体特异性抗体识别人IL-12p75异二聚体的一个或多个表位，但不与单独的p40亚基结合。 异二聚体特异性IL-12抗体以与用于中和人IL-12生物活性的效力相似的效力中和恒河猴IL-12的生物活性，使得它们可用于在恒河猴中进行体内研究的IL-12拮抗剂。

公开(公告)号：US08629257B2

公开(公告)日：2014-01-14

申请号：US12763048

申请日：2010-04-19

申请人： Susan E. Lacy ,  Emma Fung ,  Jonathan P. Belk ,  Richard W. Dixon ,  Michael Roguska ,  Paul R. Hinton ,  Shankar Kumar

发明人： Susan E. Lacy ,  Emma Fung ,  Jonathan P. Belk ,  Richard W. Dixon ,  Michael Roguska ,  Paul R. Hinton ,  Shankar Kumar

IPC分类号： C07H21/04

CPC分类号： C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6869

摘要： The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

摘要翻译： 本发明包括IL-12p40结合蛋白，特别是结合人白细胞介素-12（hIL-12）和/或人IL-23（hIL-23）的抗体。 具体地，本发明涉及作为嵌合，CDR移植和人源化抗体的抗体。 优选的抗体对hIL-12和/或hIL-23具有高亲和力，并在体外和体内中和h IL-12和/或hIL-23活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-12和/或hIL-23和用于抑制hIL-12和/或hIL-23活性，例如在患有hIL -12和/或hIL-23活性是有害的。

公开(公告)号：US08410259B2

公开(公告)日：2013-04-02

申请号：US13098337

申请日：2011-04-29

申请人： Wendy R. Gion ,  Gerald R. Carson ,  Hong Gao ,  Yune Z. Kunes

发明人： Wendy R. Gion ,  Gerald R. Carson ,  Hong Gao ,  Yune Z. Kunes

IPC分类号： C07H21/04 ,  C12N15/74

CPC分类号： C07K16/00 ,  C07K16/241 ,  C07K16/244 ,  C07K16/2854 ,  C12N15/79 ,  C12N15/85 ,  C12N2510/02 ,  C12N2830/46 ,  C12P21/02

摘要： Compositions and methods comprising recombinant expression vector elements (rEVEs) to enhance the level of expression of recombinant proteins are described. Other compositions and methods for lowering, substantially suppressing, or essentially silencing expression of a recombinant protein are also described.

摘要翻译： 描述了包含重组表达载体元件（rEVE）以增强重组蛋白质表达水平的组合物和方法。 还描述了用于降低，基本抑制或基本上沉默重组蛋白表达的其它组合物和方法。

公开(公告)号：US08287855B2

公开(公告)日：2012-10-16

申请号：US12451101

申请日：2008-04-24

申请人： Kevin P. Killeen ,  Kenneth L. Roland ,  Lawrence J. Thomas

发明人： Kevin P. Killeen ,  Kenneth L. Roland ,  Lawrence J. Thomas

IPC分类号： A61K48/00 ,  A61K39/02 ,  A61K39/106 ,  C12P1/04 ,  C12N1/20

CPC分类号： A61K39/0258 ,  A61K39/107 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/543 ,  A61K2039/70 ,  Y02A50/472 ,  Y02A50/474

摘要： Oral immunogenic compositions imparting dual protection against enterotoxigenic labile toxin (LT)-expressing Escherichia coli (ETEC) and Vibrio cholerae based on the delivery of recombinant cholera toxin B antigen by attenuated, live bacterial vectors derived from Vibrio cholerae are disclosed. The compositions exhibit dual immunogenicity and retain the ability to colonize gastrointestinal mucosa-associated lymphoid tissues.

摘要翻译： 公开了基于由霍乱弧菌引起的减毒的活细菌载体递送重组霍乱毒素B抗原的针对产生肠毒素不稳定毒素（LT）表达大肠杆菌（ETEC）和霍乱弧菌的双重保护的口服免疫原性组合物。 该组合物具有双重免疫原性并保留定殖胃肠粘膜相关淋巴组织的能力。

公开(公告)号：US08119591B2

公开(公告)日：2012-02-21

申请号：US11989802

申请日：2006-08-01

申请人： Slobodan Vukicevic ,  Mislav Jelic

发明人： Slobodan Vukicevic ,  Mislav Jelic

IPC分类号： A61K38/18

CPC分类号： A61K38/30 ,  A61K31/573 ,  A61K38/1825 ,  A61K38/1875 ,  A61K45/06 ,  A61K2300/00

摘要： Methods and compositions are described to regenerate cartilage in a partial thickness defect or area of reduced volume of articular cartilage comprising an infiltration suppressor agent and a columnar growth promoting agent.

摘要翻译： 方法和组合物被描述为在包括渗透抑制剂和柱状生长促进剂的关节软骨的部分厚度缺陷或体积减小的区域中再生软骨。